help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alkemade, H. A.
Right arrow Articles by Schalkwijk, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alkemade, H. A.
Right arrow Articles by Schalkwijk, J.

American Journal of Pathology, Vol 143, 1679-1687, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

Differential expression of SKALP/Elafin in human epidermal tumors

HA Alkemade, HO Molhuizen, IM van Vlijmen-Willems, UJ van Haelst and J Schalkwijk
Department of Dermatology, Academic Hospital Nijmegen, The Netherlands.

Recently we described a new epidermal serine proteinase inhibitor, skin- derived antileukoproteinase (SKALP), also known as elafin. SKALP/elafin was found to be absent in normal human epidermis, but can be induced in vitro and in vivo under hyperproliferative conditions. Here we studied the expression of SKALP/elafin in several types of epidermal tumors (basal cell carcinoma, squamous cell carcinoma, Bowen's disease, actinic keratosis, and keratoacanthoma). Using immunohistochemical staining SKALP/elafin appeared to be differentially expressed in these tumors. Functional measurements of anti-proteinase activity, and Western blotting of tumor extracts confirmed our findings at the histological level. In well differentiated squamous cell carcinoma, SKALP/elafin messenger RNA was demonstrated by non-radioactive in situ hybridization. We conclude that SKALP/elafin is a marker for abnormal or disturbed squamous differentiation. A possible role of SKALP/elafin in the control of tumor cell invasion is discussed.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Duvic, B. Helekar, C. Schulz, M. Cho, D. DiSepio, C. Hager, D. DiMao, P. Hazarika, B. Jackson, J. Breuer-McHam, et al.
Expression of a Retinoid-inducible Tumor Suppressor, Tazarotene-inducible Gene-3, Is Decreased in Psoriasis and Skin Cancer
Clin. Cancer Res., August 1, 2000; 6(8): 3249 - 3259.
[Abstract] [Full Text]

Home page
 J. Cell Sci.Home page
J. Alkemade, H. Molhuizen, M Ponec, J. Kempenaar, P. Zeeuwen, G. de Jongh, I. van Vlijmen-Willems, P. van Erp, P. van de Kerkhof, and J Schalkwijk
SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes
J. Cell Sci., January 8, 1994; 107(8): 2335 - 2342.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Society for Investigative Pathology.